Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ABY-035/AFO2 Formulation in Psoriasis
NCT03580278Phase 1Completed
- Sponsor
- Affibody Medical AB
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of izokibep in plaque psoriasis (2 cohorts), sponsored by Affibody Medical AB. Primary endpoint: Number of subjects with treatment-related Adverse Events at 42 Days. Started Nov 2019; status: completed.
02
Drugs
izokibep
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03580278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580278.